Gene‐protein assay
tumor, tumors, UBC, pancreatic cancer, cholangiocarcinoma
TUMOR, TUMORS, CHOLANGIOCARCINOMA
Of the 284 patients successfully screened for HER2 overexpression via IHC, 207 consented to the biomarker analyses. However, biomarker data were not available for 55 patients, owing to insufficient or poor‐quality tumor tissue or to assay‐related issues. Thus, the biomarker‐evaluable population was comprised of 152 patients.In the biomarker‐evaluable population, the tumors of 133, five, seven, and seven patients exhibited no (0% of all stained cells), focal (1%–29% of all stained cells), heterogeneous (30%–70% of all stained cells), and homogeneous (>70% of all stained cells) HER2 protein expression by IHC, respectively. Among patients with UBC, pancreatic cancer, or cholangiocarcinoma in the biomarker‐evaluable population, only 24.3% (9/37), 1.5% (1/66), and 8.2% (4/49), respectively, exhibited heterogeneous or homogeneous expression of HER2 (Table HER2 gene‐protein results by indication.
Abbreviations: A total of 207 patients consented to exploratory gene‐protein assay analysis; however, 5 samples could not be tested due to tissue wash off during the staining procedure or lack of appropriate material (no tumor content or insufficient tumor content on the slide).Correlation of HER2 protein expression with the gene amplification ratio by tumor type. Test results from an analysis of variance based on the model: 